

Diabetic Peripheral Neuropathy Therapeutic and Overview Pipeline Review H2

*Diabetic Peripheral Neuropathy
Treatment Pipeline Review H2 2016*

PUNE, INDIA, November 15, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Diabetic Peripheral Neuropathy](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/619250-diabetic-peripheral-neuropathy-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy
- The report reviews pipeline therapeutics for Diabetic Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities



WISE GUY
R E P O R T S

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

- The report reviews key players involved Diabetic Peripheral Neuropathy therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Peripheral Neuropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Diabetic Peripheral Neuropathy Overview 7

Therapeutics Development 8

Pipeline Products for Diabetic Peripheral Neuropathy - Overview 8

Pipeline Products for Diabetic Peripheral Neuropathy - Comparative Analysis 9

Diabetic Peripheral Neuropathy - Therapeutics under Development by Companies 10

Diabetic Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 11

Diabetic Peripheral Neuropathy - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Diabetic Peripheral Neuropathy - Products under Development by Companies 15

Diabetic Peripheral Neuropathy - Products under Investigation by Universities/Institutes 16

Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development 17

Achelios Therapeutics, Inc. 17

Celgene Corporation 18

Commence Bio, Inc. 19

Crescita Therapeutics Inc. 20

Glenmark Pharmaceuticals Ltd. 21

Relief Therapeutics S.A. 22

ViroMed Co., Ltd. 23

Diabetic Peripheral Neuropathy - Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
atexakin alfa - Drug Profile 33

Access Report @ <https://www.wiseguyreports.com/reports/619250-diabetic-peripheral-neuropathy-pipeline-review-h2-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.